Heart failure & cardiomyopathies
Suspected de novo heart failure in outpatient care: the REVOLUTION heart failure (HF) study
Authors' conclusion
Patients with suspected HF and elevated NT-proBNP had high mortality and morbidity in the weeks after presentation, and accrued substantial healthcare costs
Study context
- Population
- Outpatients presenting for the first time with a sign or symptom of HF and elevated NT-proBNP, 2015–2020, Sweden
- Participants
- 5,942 vs 2,048
- Exposure
- Suspected de novo HF vs matched controls
- Suspected de novo HFn = 5,942
- Matched controlsn = 2,048reference
- Outcome
- All-cause death, HF hospitalization and healthcare costs
- Follow-up
- 1 year
Methodological detailsmatched controls, two healthcare regions in Sweden
- Matched controls
- Two healthcare regions in Sweden
Main finding
As reported in the abstract
All-cause death and HF hospitalization
| Group | All-cause death | HF hospitalization |
|---|---|---|
| Suspected de novo HF | 11.7 events/100 person-years | 12.5 events/100 person-years |
| Matched controls | 6.5 events/100 person-years | 2.2 events/100 person-years |
All-cause death
Suspected de novo HF11.7 events/100 person-years
Matched controls6.5 events/100 person-years
HF hospitalization
Suspected de novo HF12.5 events/100 person-years
Matched controls2.2 events/100 person-years
Observational data: associations, not effects.
Further findings
HF diagnosis within 1 year
- Received a HF diagnosis
- 29%
Event rates by NT-proBNP level
- Rates higher with higher NT-proBNP levels
Initiation of new HF guideline-directed medications
- Initiation of new medications was variable
Healthcare costs
- Higher in suspected de novo HF than matched controls, driven mostly by HF and CKD
Original publication
Suspected de novo heart failure in outpatient care: the REVOLUTION HF study. Eur Heart J. Published 12 February 2025. doi:10.
Summarised from the published abstract; every number is checked against it